Clinical Trial Update: Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes [Phase 1]

View source ↗

Summary

This phase 1 trial update describes evaluating the safety and determining the optimal dose of novobiocin in patients with tumors that harbor DNA repair gene alt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Unresectable Cancer

Drugs mentioned

• Novobiocin (novobiocin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING